Linden Adds Operating Partner

Linden Capital Partners has added Joseph Bernardo to its team as a new Operating Partner.

Mr. Bernardo has significant M&A experience and has been involved with over 25 due diligences, acquisitions, and integrations since the start of his career. He most recently served as the President of the Next-Generation Sequencing and Oncology division at Thermo Fisher Scientific. Mr. Bernardo has been with Thermo Fisher since 2008 and in addition to his work with next-generation technologies he was the president of the company’s ImmunoDiagnostics, Anatomic Pathology, and Fisher Healthcare divisions. Prior to joining Thermo Fisher, he served as the Senior Vice President of the Central Lab Business Unit at Siemens Healthcare. Mr. Bernardo holds a BS in Chemistry from Lafayette College and a MA in Chemistry from the University of Virginia. He is currently a Senior Advisor to The Boston Consulting Group.

“After spending my career with Thermo Fisher, Siemens, and Abbott, I am excited to partner with a healthcare exclusive private equity firm that respects and values my management, operational, R&D, and M&A experience in the diagnostics industry,” said Mr. Bernardo.

Mr. Bernardo will serve as the Chairman of SeraCare and will also act as the lead Operating Partner for Linden’s investments in future diagnostics and life sciences companies. Linden acquired SeraCare, a maker of diagnostic controls, reagents and molecular biomarkers used in a variety of in vitro diagnostics, in April 2012.

“Joe has a plethora of relevant experience and brings an unparalleled knowledge base in the diagnostics arena,” said Brian Miller, a Managing Partner at Linden. “We are thrilled for him to join SeraCare as Chairman and continue to build upon Linden’s expertise in diagnostics.”

Linden Capital Partners is focused exclusively on leveraged buyouts in the healthcare and life science industries with a specific interest in medical products, specialty distribution, pharmaceutical, and services segments of healthcare. Linden’s strategy is based upon three elements: healthcare and life science industry specialization; integrated financial and operating expertise; and strategic relationships with large corporations. The firm is based in Chicago (www.lindenllc.com).

© 2018 Private Equity Professional | January 3, 2018

Print Friendly, PDF & Email

Related Articles

New Head of PE at Invesco Publicly-traded Invesco (NYSE: IVZ) has expanded its Invesco Private Capital business by naming Carl Stanton as a Managing Partner and Head of Private...
Bertram Promote Three Bertram Capital has promoted Michelle Chao and Alex Goldscher to Vice President, and Soraya Hoberman to Associate. "The promotions recognize the si...
Jason Urband Makes Partner Lariat Partners has promoted Jason Urband to Partner. Mr. Urband is active in evaluating new investments for Lariat particularly in the industrial ser...
“The Exciting Game Without Any Rules” Valuations on middle-market private M&A transactions continued their torrid upward surge in the fourth quarter, according to GF Data’s just releas...
Bertram Hits Fund III Hard Cap Bertram Capital has held a hard cap final closing of Bertram Growth Capital III LP and Bertram Growth Capital III-A LP (collectively Fund III) with a ...
The Return of the Megafunds McKinsey & Company has published its 2018 annual review of private markets that confirms global fundraising and assets under management (AUM) reac...